undamentalytics Newsletter
Sign in

Opko Health, Inc. (OPK) stock

Add to watchlist

Add holding +

NASDAQ: OPK Nasdaq Pharmaceuticals Next results ~November 4, 2026

Opko Health, Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: data-quality checks not passed.

Price vs value

Under review: data-quality checks not passed. We'll show the comparison once resolved.

Opko Health, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders2 buying, 0 selling33 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds96 adding, 82 cuttingOf 20 active managers that changed their stake, 11 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Opko Health files

Where Opko Health stands after its latest 10-Q/A

Revenue for the twelve months to June 2026 was $588m, down 11.5% on a year earlier, a smaller fall than the 15.7% decline a quarter earlier. Free-cash-flow margin rose to -22.8% from -39.0% a year earlier. Operating margin widened to -8.2% from -34.3%. It passes 5 of our 7 financial-health checks.

Our model value for Opko Health is under review, so past values are not shown until it is resolved.

Source: 10-Q/A filed August 28, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 4, 2026 (estimated)

Opko Health, Inc.'s trailing-twelve-month revenue fell 11.5% year on year, with a free-cash-flow margin of -22.8%.

Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 76% in the quarter to 2026-06-30, the 3rd beat in the last four quarters.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Margins widening. Operating margin is up 26.0 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.3bn.

Things to watch

  • Revenue shrinking. Revenue fell 11.5% over the last 12 months.
  • Loss-making. Operating margin is -8.2%: costs exceed revenue.
  • Burning cash. Free cash flow was -22.8% of revenue over the last 12 months.
  • Share dilution. Diluted shares rose 4.9% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 57% and a beta of 0.9 against the S&P 500.

Latest results: FY2026 Q2

Filed August 28, 2026
Earnings per share
-$0.03 against an average estimate of -$0.11: beat by 76.3%
Revenue
$164m, up 4.3% on a year earlier
Share reaction
+35.2% in the first session after the results on July 27, 2026, against +0.3% for the S&P 500
Next report
November 4, 2026; average EPS estimate -$0.06

Opko Health's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+3.6%
  • 1 week+5.5%
  • 1 month+10.3%
  • This year+36.5%
  • 1 year+26.5%
  • 5 years-61.2%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$588M
Operating margin
-8.2%
Net margin
-12.4%
EPS (TTM, diluted)
$-0.10

Growth

Revenue growth
−11.5%
Change in growth rate
+4.2 pts

Cash

Free cash flow (TTM)
-$134M
FCF margin
-22.8%
Stock pay % of revenue
1.8%

Earnings

Last results
July 27, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Agreement
  2. Announcement
  3. Agreement
  4. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Opko Health, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Opko Health, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 8.2%: the 10-year Treasury yield (4.9%) plus a beta of 0.73 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$0.5 ~$0.3–$0.6 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. — Does not apply: This model is withheld pending its input or assumption review.
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$0.4 ~$0.4–$0.6 Included
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Opko Health, Inc. with Pharmaceuticals in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025Now
Share price$10.05$9.30$4.90$3.01$1.47$3.95$4.81$1.25$1.51$1.47$1.26$1.72
Market value$4.9bn$5.2bn$2.7bn$1.7bn$875m$2.5bn$3.1bn$899m$1.1bn$1.0bn$946m$1.3bn
+ Net debt (− = net cash)−$110m−$113m$37m$46m$194m$204m$85m$137m$120m$184m−$20m$48m
Enterprise value$4.8bn$5.1bn$2.8bn$1.7bn$1.1bn$2.7bn$3.2bn$1.0bn$1.3bn$1.2bn$926m$1.4bn
Multiples
Price / sales 10.0x4.6x2.8x1.7x1.0x1.8x1.8x0.9x1.3x1.4x1.6x2.2x
Price / earnings —————82.7x——————
Price / free cash flow 32.0xn/m———n/mn/m—————
EV / EBITDA —n/m———19.1x32.9x————32.9x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

21 /100

Weak moat

How hard Opko Health's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -8.8% of total assets over 10 years.

  • Durability 10 / 20

    Operating margin has been a median -18.1%; its worst year was -37.2%.

  • Cash conversion 1 / 20

    Free cash flow was positive in 1 of 10 years, at a median -13.4% of revenue.

  • Discipline 10 / 20

    The diluted share count rose 22.8% over five years; stock-based pay has been a median 1.6% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (26 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 4, 2026, after the close. Analysts expect revenue of $137m and EPS of −$0.06 (range −$0.08 to −$0.05) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.21 — $570m −6%
Next −$0.34 −64% $495m −13%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −44.7% on 90 days ago. In the last 30 days, 1 analyst raised Opko Health, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Opko Health, Inc., last 90 days
−$0.40 −$0.30 −$0.20 −$0.10 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.38 Current fiscal year, 60 days ago: −$0.22 Current fiscal year, 30 days ago: −$0.22 Current fiscal year, 7 days ago: −$0.21 Current fiscal year, Now: −$0.21 −$0.21 Next fiscal year, 90 days ago: −$0.32 Next fiscal year, 60 days ago: −$0.28 Next fiscal year, 30 days ago: −$0.28 Next fiscal year, 7 days ago: −$0.27 Next fiscal year, Now: −$0.34 −$0.34

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.38−$0.32
60 days ago −$0.22−$0.28
30 days ago −$0.22−$0.28
7 days ago −$0.21−$0.27
Now −$0.21−$0.34

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.11 −$0.03 +76.3%
Mar 2026 −$0.07 −$0.07 −6.2%
Dec 2025 −$0.07 −$0.04 +48.9%
Sept 2025 −$0.04 $0.03 +166.7%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

6 analysts, Oct 2026
Buy583%
Hold117%
Sell00%

Monthly trend

  1. Oct 20263216
  2. Sep 20262226
  3. Aug 20262226

Counts of recommendations published by analysts covering Opko Health, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
8.2%
of tradable shares
Days to cover
7.73
at average volume
Short interest, 1 month
−5%
to October 15, 2026
Held by institutions
28%
of shares
Held by insiders
50.5%
of shares
Employees
2,275
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +26.5%

$1.36 on October 31, 2025 to $1.72

ThenNowEffect
Revenue (last 12 months) $664m $588m −11.5%
P/S multiple 1.6x 2.2x +38.5%
Share count 789m 765m +3.1%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years +27.4%

$1.35 on November 3, 2023 to $1.72

ThenNowEffect
Revenue (last 12 months) $868m $588m −32.3%
P/S multiple 1.2x 2.2x +91.4%
Share count 752m 765m −1.7%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
OPK+22%−74%+21%−3%−14%+37%
Industry peers (median)−20%−49%−14%−2%+9%−14%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
OPK50%25%50%58%33%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
OPK−44%−79%−43%−45%−39%−24%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 3, 2015: 93% from December 13, 2016 to March 18, 2024. Getting back needed a 1269% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$1.10 – $1.73
From 52-week high
−0.6%
vs 50-day average
+9.7%
vs 200-day average
+27.8%
Volatility (1 year)
57%
Beta vs S&P 500
0.88

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±6.9%
After a week
4 up, 8 down
typical move ±7.6%
After a month
9 up, 3 down
typical move ±9.3%
Results releasedNext dayS&P 500 next day5 days21 days
July 27, 2026 +35.2% +0.3% +7.4% +22.1%
April 28, 2026 −7.5% −0.5% −5.8% +19.2%
February 26, 2026 +1.7% −1.0% −0.8% −5.1%
October 29, 2025 +1.4% −1.1% −6.9% −5.6%
July 31, 2025 −11.2% −2.0% −8.2% +3.0%
April 30, 2025 −3.6% +0.7% −10.7% −2.9%
February 27, 2025 +4.8% −0.1% +13.9% +2.4%
November 7, 2024 +3.4% +1.2% +10.2% +7.5%
August 7, 2024 +6.7% +1.6% +14.2% +16.4%
May 7, 2024 −5.3% +0.1% −0.8% +1.5%
February 27, 2024 −1.0% +0.1% −7.0% +7.0%
November 6, 2023 −0.7% +0.5% −5.2% +18.5%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Revenue (TTM) Opko Health, Inc.
$500M $600M $700M $800M $900M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $866.9M Revenue (TTM), FY23 Q4: $863.5M Revenue (TTM), FY24 Q1: $799.6M Revenue (TTM), FY24 Q2: $716.4M Revenue (TTM), FY24 Q3: $711.4M Revenue (TTM), FY24 Q4: $713.1M Revenue (TTM), FY25 Q1: $689.4M Revenue (TTM), FY25 Q2: $664M Revenue (TTM), FY25 Q3: $642.1M Revenue (TTM), FY25 Q4: $606.9M Revenue (TTM), FY26 Q1: $581.1M Revenue (TTM), FY26 Q2: $587.9M $587.9M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $866.9M
FY23 Q4 $863.5M
FY24 Q1 $799.6M
FY24 Q2 $716.4M
FY24 Q3 $711.4M
FY24 Q4 $713.1M
FY25 Q1 $689.4M
FY25 Q2 $664M
FY25 Q3 $642.1M
FY25 Q4 $606.9M
FY26 Q1 $581.1M
FY26 Q2 $587.9M
Revenue growth, TTM YoY Opko Health, Inc.
-30% -20% -10% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: -29.0% Revenue growth, TTM YoY, FY23 Q4: -14.0% Revenue growth, TTM YoY, FY24 Q1: -12.4% Revenue growth, TTM YoY, FY24 Q2: -17.5% Revenue growth, TTM YoY, FY24 Q3: -17.9% Revenue growth, TTM YoY, FY24 Q4: -17.4% Revenue growth, TTM YoY, FY25 Q1: -13.8% Revenue growth, TTM YoY, FY25 Q2: -7.3% Revenue growth, TTM YoY, FY25 Q3: -9.7% Revenue growth, TTM YoY, FY25 Q4: -14.9% Revenue growth, TTM YoY, FY26 Q1: -15.7% Revenue growth, TTM YoY, FY26 Q2: -11.5% -11.5%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 -29.0%
FY23 Q4 -14.0%
FY24 Q1 -12.4%
FY24 Q2 -17.5%
FY24 Q3 -17.9%
FY24 Q4 -17.4%
FY25 Q1 -13.8%
FY25 Q2 -7.3%
FY25 Q3 -9.7%
FY25 Q4 -14.9%
FY26 Q1 -15.7%
FY26 Q2 -11.5%
Operating margin (TTM) Opko Health, Inc.
-40% -30% -20% -10% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -16.5% Operating margin (TTM), FY23 Q4: -18.2% Operating margin (TTM), FY24 Q1: -24.7% Operating margin (TTM), FY24 Q2: -37.2% Operating margin (TTM), FY24 Q3: -37.9% Operating margin (TTM), FY24 Q4: -32.7% Operating margin (TTM), FY25 Q1: -33.2% Operating margin (TTM), FY25 Q2: -34.3% Operating margin (TTM), FY25 Q3: -17.5% Operating margin (TTM), FY25 Q4: -19.3% Operating margin (TTM), FY26 Q1: -17.4% Operating margin (TTM), FY26 Q2: -8.2% -8.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -16.5%
FY23 Q4 -18.2%
FY24 Q1 -24.7%
FY24 Q2 -37.2%
FY24 Q3 -37.9%
FY24 Q4 -32.7%
FY25 Q1 -33.2%
FY25 Q2 -34.3%
FY25 Q3 -17.5%
FY25 Q4 -19.3%
FY26 Q1 -17.4%
FY26 Q2 -8.2%
FCF margin (TTM) Opko Health, Inc.
-40% -30% -20% -10% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -4.7% FCF margin (TTM), FY23 Q4: -5.2% FCF margin (TTM), FY24 Q1: -7.4% FCF margin (TTM), FY24 Q2: -12.0% FCF margin (TTM), FY24 Q3: -28.1% FCF margin (TTM), FY24 Q4: -29.2% FCF margin (TTM), FY25 Q1: -29.9% FCF margin (TTM), FY25 Q2: -39.0% FCF margin (TTM), FY25 Q3: -33.0% FCF margin (TTM), FY25 Q4: -31.4% FCF margin (TTM), FY26 Q1: -30.0% FCF margin (TTM), FY26 Q2: -22.8% -22.8%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -4.7%
FY23 Q4 -5.2%
FY24 Q1 -7.4%
FY24 Q2 -12.0%
FY24 Q3 -28.1%
FY24 Q4 -29.2%
FY25 Q1 -29.9%
FY25 Q2 -39.0%
FY25 Q3 -33.0%
FY25 Q4 -31.4%
FY26 Q1 -30.0%
FY26 Q2 -22.8%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2009 Dec 2009 2010 Dec 2010 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 4 28 28 47 97 91 492 1,117 966 990 902 1,435 1,775 1,004 863 713 607 588
Gross profit 2 15 11 19 86 82 298 553 — — — — — 288 318 219 206 240
EBITDA −22 −9 −19 −27 −64 −131 −56 0 −174 −74 −180 143 97 −118 −52 −54 −26 41
Operating income −22 −11 −23 −37 −80 −146 −98 −97 −276 −171 −274 58 19 −226 −157 −152 −117 −48
Net income −30 −19 −1 −29 −114 −172 −30 −48 −305 −153 −315 31 −30 −328 −189 −53 −226 −73
Diluted EPS — −$0.08 −$0.01 −$0.11 −$0.32 −$0.41 −$0.06 −$0.10 −$0.55 −$0.27 −$0.53 $0.05 −$0.05 −$0.46 −$0.25 −$0.08 −$0.30 −$0.10
Growth (year on year)
Revenue — +545.0% −1.8% +68.1% +105.2% −5.6% +439.6% +127.3% −13.6% +2.5% −8.9% +59.1% +23.6% −43.4% −14.0% −17.4% −14.9% −11.5%
EBITDA — — — — — — — — — — — — −31.9% −220.7% — — — —
Operating income — — — — — — — — — — — — −67.5% — — — — —
Net income — — — — — — — — — — — — −198.6% — — — — —
Diluted EPS — — — — — — — — — — — — −200.0% — — — — —
Margins
Gross margin 34.9% 52.6% 38.4% 40.7% 89.2% 89.7% 60.7% 49.5% — — — — — 28.7% 36.8% 30.6% 33.9% 40.8%
EBITDA margin −488.5% −31.3% −69.2% −57.6% −66.7% −143.6% −11.4% 0.0% −18.0% −7.5% −20.0% 10.0% 5.5% −11.7% −6.0% −7.6% −4.2% 7.1%
Operating margin −501.3% −39.1% −82.9% −79.2% −82.5% −160.0% −20.0% −8.6% −28.6% −17.3% −30.4% 4.0% 1.1% −22.5% −18.2% −21.3% −19.3% −8.2%
Net margin −681.6% −66.4% −4.6% −61.7% −118.5% −188.4% −6.1% −4.3% −31.6% −15.5% −34.9% 2.1% −1.7% −32.7% −21.9% −7.5% −37.2% −12.4%
Free-cash-flow margin −533.7% −68.4% −73.1% −57.2% −61.8% −104.4% 31.2% 1.2% −14.3% −13.8% −20.5% 0.4% 0.3% −11.9% −5.2% −29.2% −31.4% −22.8%
Cash flow
Cash from operations −23 −19 −19 −25 −56 −90 164 32 −92 −109 −173 39 38 −95 −28 −183 −179 −123
Capital spending 0 1 2 1 4 5 11 19 47 28 13 34 32 25 16 25 12 11
Free cash flow −24 −19 −20 −27 −60 −95 153 13 −139 −137 −185 6 6 −120 −44 −208 −191 −134
Stock-based pay 4 7 7 5 11 15 26 43 28 22 13 9 14 19 11 11 11 11
Free cash flow after stock pay −28 −26 −27 −32 −71 −110 127 −29 −167 −159 −199 −3 −7 −138 −56 −220 −202 −145
Balance sheet
Cash 43 18 72 27 186 97 194 169 91 96 85 72 135 153 96 427 364 301
Total debt 0 29 18 38 224 145 84 56 128 143 280 276 220 290 216 611 344 349
Net debt (negative = net cash) −43 11 −54 11 39 48 −110 −113 37 46 194 204 85 137 120 184 −20 48
Diluted shares 233m 255m 281m 296m 355m 422m 488m 556m 559m 563m 595m 641m 648m 719m 752m 694m 751m 765m
Returned to shareholders
Buybacks — — 8 0 0 — — — — — — — — 0 0 90 47 47
Total returned — — 8 0 0 — — — — — — — — 0 0 90 47 47

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

5 of 7 checks passed · June 30, 2026
What it owns · $1.8bn
Short-term assets $500mLonger-term assets $1.3bn
What it owes, and who funded it · $1.8bn
Short-term liabilities $149mLonger-term liabilities $496mShareholders' equity $1.2bn
  • Short-term assets cover short-term liabilities $500m of assets due within a year against $149m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $500m short-term assets against $496m of longer-dated liabilities.
  • More cash than debt $301m of cash against $3m of debt.
  • Debt below 40% of shareholders' equity Debt is 0% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 12% to 0% over five years.
  • A year's operating cash flow covers at least 20% of debt −$123m of operating cash flow against $3m of debt.
  • Operating profit covers interest at least five times over Operating income of −$48m against −$63m of interest.

From Opko Health, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2026 Q2 TTM
Buybacks (TTM)
$46.6M
Returned to shareholders
-35%
of free cash flow
Buybacks, last 3 fiscal years
$137M
Total shareholder yield
3.6%
dividends 0.0% + buybacks 3.6% of market value
R&D spending
21.3%
of revenue
Sales & admin spending
35.0%
of revenue
Days sales outstanding
51 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in pharmaceuticals
Last 12 months unless stated OPK ALVO EBS TVTX AMPH PCRX Median
Revenue, last 12 months $588m $586m $649m $651m $730m $746m $296m
Revenue growth, last 12 months −11.5% 19.7% −17.7% 49.4% 1.0% 5.7% 9.7%
Revenue growth, 3-year average −12.2% — −16.2% 71.3% 10.5% 3.7% 5.2%
Revenue growth, latest quarter 4.3% — −52.4% 36.2% 5.4% 6.2% 6.4%
Gross margin 40.8% 59.8% 48.4% 98.5% 47.7% 79.2% 60.1%
Operating margin −8.2% 13.3% −27.7% −20.5% 15.7% 2.7% −5.9%
Operating margin, 3-year average −26.6% — −8.5% −72.3% 24.3% 0.4% −8.5%
Net margin −12.4% 4.8% −40.2% −18.7% 10.8% 2.0% −7.4%
Cash from operations / revenue −21.0% −8.6% 30.8% 27.1% 25.3% 25.2% 9.4%
Free-cash-flow margin −22.8% −19.6% 29.0% 27.1% 20.9% 24.1% 8.1%
Free-cash-flow margin, 3-year average −24.6% — 13.8% −40.1% 20.5% 22.5% 6.6%
Stock pay / revenue 1.8% 1.3% 2.8% 11.2% 4.0% 7.5% 3.6%
Change in share count 4.9% 8.7% −0.6% −1.7% −7.8% −2.8% 2.0%

Median of all 76 companies we cover in pharmaceuticals. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue YoY
Services $370M ▼ 23.0%
Products $157M ▲ 1.2%
Transfer of Intellectual Property and Other $79.7M ▲ 3.0%
Rayaldee $59.4M ▼ 14.3%

These categories overlap or exclude eliminations, so shares aren't shown.

Geography
Region Revenue Share YoY
United States $436M 71.9% ▼ 20.2%
CL $62.4M 10.3% ▼ 4.1%
Ireland $51.4M 8.5% ▲ 6.2%
ES $26.7M 4.4% ▲ 8.5%
Mexico $25.5M 4.2% ▲ 6.9%
Other Countries $4.3M 0.7% ▲ 36.8%
Israel $522,000 0.1% ▼ 70.5%

From Opko Health, Inc.'s 10-K filed February 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$304M
Institutions reporting
220
Shares held vs prior quarter
▲ 0.8%
Positions opened / closed
21 / 31

Top buyers and sellers, Q2 2026: 96 institutions bought and 82 sold ; the biggest buyer was Highbridge Capital Management LLC (+3.6M shares) and the biggest seller UBS Group AG (−1.1M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Rubric Capital Management LP $71.7M 47.8M 23.6% 0.0%
Blackrock, Inc. $55.5M 37.0M 18.2% ▲ 2.1%
Vanguard Capital Management LLC $22.5M 15.0M 7.4% ▲ 3.2%
Vanguard Portfolio Management LLC $22.4M 14.9M 7.4% ▲ 1.1%
Geode Capital Management, LLC $17.4M 11.6M 5.7% ▲ 2.5%
State Street Corp $15.5M 10.3M 5.1% ▲ 8.5%
Goldman Sachs Group Inc $10.6M 7.0M 3.5% ▼ 8.3%
UBS Group AG $7.5M 5.0M 2.5% ▼ 17.5%
Whitefort Capital Management, LP $6.8M 4.5M 2.2% ▲ 6.1%
Northern Trust Corp $5.6M 3.8M 1.9% ▲ 3.8%
Highbridge Capital Management LLC $5.4M 3.6M 1.8% New
Charles Schwab Investment Management Inc $5.4M 3.6M 1.8% ▲ 0.6%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Opko Health, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $3M 33 trades by 2 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $3M net buying
Insider Date Trade Shares Price Value
Paganelli John A Director March 20, 2026 Buy 10,000 $1.14 $11,400
Frost Gamma Investments Trust 10% owner November 21, 2025 Buy 192,870 $1.34 $258,446
Frost Gamma Investments Trust 10% owner November 21, 2025 Buy 102,371 $1.30 $133,082
Frost Gamma Investments Trust 10% owner November 21, 2025 Buy 3,894 $1.32 $5,140
Frost Gamma Investments Trust 10% owner November 21, 2025 Buy 191,490 $1.33 $254,682
Frost Gamma Investments Trust 10% owner November 21, 2025 Buy 89,375 $1.33 $118,869
Frost Gamma Investments Trust 10% owner November 20, 2025 Buy 13,664 $1.35 $18,446
Frost Gamma Investments Trust 10% owner November 20, 2025 Buy 47,105 $1.33 $62,650
Frost Gamma Investments Trust 10% owner November 20, 2025 Buy 119,129 $1.32 $157,250
Frost Gamma Investments Trust 10% owner November 20, 2025 Buy 211,948 $1.33 $281,891
Frost Gamma Investments Trust 10% owner November 20, 2025 Buy 1,757 $1.35 $2,372
Frost Gamma Investments Trust 10% owner November 20, 2025 Buy 24,579 $1.34 $32,936

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 3 trades and filings

No trades in Opko Health, Inc. disclosed in the last 12 months; 3 earlier trades on record.

  • Carlos Curbelo(FL):Purchase, $1,001 - $15,000, traded September 26, 2017, filed October 3, 2017
  • Carlos Mr Curbelo(FL):Purchase, $1,001 - $15,000, traded March 2, 2017, filed March 2, 2017
  • Carlos Mr Curbelo(FL):Purchase, $1,001 - $15,000, traded February 7, 2017, filed February 7, 2017

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around October 28, 2026 estimated from the company's past filing pattern, not announced

  • July 27, 2026
  • April 28, 2026
  • February 26, 2026
  • October 29, 2025
  • July 31, 2025
  • April 30, 2025

Recent SEC filings

Data status

When each part of this page on Opko Health, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Opko Health, Inc. in brief

What does Opko Health, Inc. do?
Opko Health, Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.
What is Opko Health, Inc.'s stock ticker?
Opko Health, Inc. trades under the ticker OPK on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Opko Health, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Opko Health, Inc. reported revenue of $588M, 11.5% lower than a year earlier, according to its SEC filings.
What is Opko Health, Inc.'s free cash flow?
Opko Health, Inc.'s free-cash-flow margin is -22.8% of revenue over the trailing twelve months.
Who are Opko Health, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Rubric Capital Management LP, Blackrock, Inc. and Vanguard Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Opko Health, Inc.'s market cap?
On November 2, 2026, Opko Health, Inc.'s market capitalisation was about $1.3B and net debt of $48.3M. Market figures come from third-party market data and may be delayed.
How much debt does Opko Health, Inc. have?
Opko Health, Inc.'s debt-to-equity ratio is 0.2%, from its latest balance sheet (12.2% five years earlier). The financial health section below sets out its other solvency checks.
Who are Opko Health, Inc.'s competitors?
In our Pharmaceuticals peer group, the companies closest to Opko Health, Inc. are Alvotech, Emergent Biosolutions Inc., Travere Therapeutics, Inc., Amphastar Pharmaceuticals, Inc. and Pacira Biosciences, Inc. The side-by-side comparison below sets their revenue, margins and growth against Opko Health, Inc.'s.
Are insiders buying or selling Opko Health, Inc. stock?
Over the last 12 months, Opko Health, Inc.'s directors and officers reported 33 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Opko Health, Inc.'s next earnings date?
Around November 4, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Opko Health, Inc. announces its own schedule.